Bridging therapies and liver transplantation in acute liver failure

Scandinavian Journal of Surgery

Volumn 100, Issue 1, 2011, Pages 8-13

  Kantola, T ^a   Ilmakunnas, M ^a   Koivusalo, A M ^a   Isoniemi, H ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Acute liver failure; Albumin dialysis; Artificial liver assist device; Hepatic encephalopathy; Liver transplantation; MARS; Molecular adsorbent recirculating system

Indexed keywords

EID: 79952914564     PISSN: 14574969     EISSN: None     Source Type: Journal    
DOI: 10.1177/145749691110000103     Document Type: Article

References (54)

1. Mitzner SR, Stange J, Klammt S, et al: Albumin dialysis MARS: knowledge from 10 years of clinical investigation. ASAIO J 2009;55:498-502
2. European Liver Transplant Registry 2009 - The European Liver and Intestinal Transplant Association (ELITA). http://www.ELTR.org
3. Lee WM, Squires RH, Jr, Nyberg SL, et al: Acute liver failure: Summary of a workshop. Hepatology 2008;47:1401-1415
4. Trey C, Davidson CS: The management of fulminant hepatic failure. Prog Liver Dis 1970;3:282-298
5. O'Grady JG, Schalm SW, Williams R: Acute liver failure: redefining the syndromes. Lancet 1993;342(8866):273-275
6. Riordan SM, Williams R: Perspectives on liver failure: past and future. Semin Liver Dis 2008;28):137-141
7. Lee WM: Etiologies of acute liver failure. Semin Liver Dis 2008;28:142-153
8. Ostapowicz G, Fontana RJ, Schiodt FV, et al: Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Inter Med 2002;137:947-954
9. Brandsaeter B, Hockerstedt K, Friman S, et al: Fulminant hepatic failure: outcome after listing for highly urgent liver transplantation-12 years experience in the Nordic countries. Liver Transpl 2002;8:1055-1062
10. Saliba F, Camus C, Durand F, et al: Randomized controlled multicenter trial evaluating the efficacy and safety of albumin dialysis with MARS in patients with fulminant and subfulminant hepatic failure. Hepatology 2008;48:4 (Suppl 1):LB1
11. Bernal W, Cross TJ, Auzinger G, et al: Outcome after waitlisting for emergency liver transplantation in acute liver failure: a single centre experience. J Hepatol 2009;50:306-313
12. Bjøro K, Kirkegaard P, Ericzon BG, et al: Is a 3-day limit forhighly urgent liver transplantation for fulminant hepatic failure appropriate, and is the diagnosis in some cases incorrect? Transplant Proc 2001;33:2511-2513
13. O'Grady JG, Alexander GJ, Hayllar KM, et al: Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989;97:439-445
14. Bailey B, Amre DK, Gaudreault P: Fulminant hepatic failure secondary to acetaminophen poisoning: a systematic review and meta-analysis of prognostic criteria determining the need for liver transplantation. Crit Care Med 2003;31:299-305
15. McPhail MJ, Wendon JA, Bernal W: Meta-analysis of performance of Kings's College Hospital Criteria in prediction of outcome in non-paracetamol-induced acute liver failure. J Hepatol 2010;53(3):492-499
16. Polson J: Assessment of prognosis in acute liver failure. Semin Liver Dis 2008;28:218-226
17. Bernuau J, Goudeau A, Poynard T, et al. Multivariate analysis of prognostic factors in fulminant hepatitis B. Hepatology 1986;6:648-651
18. Bernal W, Donaldson N, Wyncoll D, Wendon J: Blood lactate as an early predictor of outcome in paracetamol-induced acute liver failure: a cohort study. Lancet 2002;359(9306):558-563
19. Schmidt LE, Dalhoff K: Alpha-fetoprotein is a predictor of outcome in acetaminophen-induced liver injury. Hepatology 2005;41:26-31
20. Steadman RH, Van Rensburg A, Kramer DJ: Transplantation for acute liver failure: perioperative management. Curr Opin Organ Transplant 2010;15:368-373
21. Devlin J, Wendon J, Heaton N, et al: Pretransplantation clinical status and outcome of emergency transplantation for acute liver failure. Hepatology 1995;21:1018-1024
22. Schiodt FV, Chung RT, Schilsky ML, et al: Outcome of acute liver failure in the elderly. Liver Transpl 2009;15:1481-1487
23. Bernal W, Auzinger G, Dhawan A, et al Acute liver failure. Lancet 2010;376(9736):190-201
24. Umeshita K, Fujiwara K, Kiyosawa K, et al: Operative morbidity of living liver donors in Japan. Lancet 2003;362(9385):687-690
25. Quaglia A, Portmann BC, Knisely AS, et al: Auxiliary transplantation for acute liver failure: Histopathological study of native liver regeneration. Liver Transpl 2008;14:1437-1448
26. Farmer DG, Anselmo DM, Ghobrial RM, et al: Liver transplantation for fulminant hepatic failure: experience with more than 200 patients over a 17-year period. Ann Surg 2003;237:666-675
27. Leithead JA, Ferguson JW, Bates CM, et al: The systemic inflammatory response syndrome is predictive of renal dysfunction in patients with non-paracetamol-induced acute liver failure. Gut 2009;58:443-449
28. Ede RJ, Gimson AE, Bihari D, et al: Controlled hyperventilation in the prevention of cerebral oedema in fulminant hepatic failure. J Hepatol 1986;2:43-51
29. Ford RM, Sakaria SS, Subramanian RM: Critical care management of patients before liver transplantation. Transplant Rev (Orlando) 2010;24:190-206
30. Stravitz RT, Larsen FS: Therapeutic hypothermia for acute liver failure. Crit Care Med 2009;37(7 Suppl):S258-S264
31. McKenzie TJ, Lillegard JB, Nyberg SL: Artificial and bioartificial liver support. Semin Liver Dis 2008;28:210-217
32. Demetriou AA, Brown RS, Jr, Busuttil RW, et al: Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. Ann Surg 2004;239:660-670
33. Van de Kerkhove MP, Hoekstra R, Chamuleau RA, et al: Clinical application of bioartificial liver support systems. Ann Surg 2004;240:216-230
34. O'Grady JG, Gimson AE, O'Brien CJ, et al: Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology 1988;94:1186-1192
35. Larsen FS, Wendon J, Hockerstedt K, et al: Liver assisting with high-volume plasma exchange in patients with acute liver failure. Hepatology 2010;52(Suppl 1):376A114
36. Falkenhagen D, Strobl W, Vogt G, et al: Fractionated plasma separation and adsorption system: a novel system for blood purification to remove albumin bound substances. Artif Organs 1999;23:81-86
37. Senturk E, Esen F, Ozcan PE, et al: The treatment of acute liver failure with fractionated plasma separation and adsorption system: Experience in 85 applications. J Clin Apher 2010;25:195-201
38. Grodzicki M, Kotulski M, Leonowicz D, et al: Results of treatment of acute liver failure patients with use of the Prometheus FPSA system. Transplant Proc 2009;41:3079-3081
39. Meijers BK, Verhamme P, Nevens F, et al: Major coagulation disturbances during fractionated plasma separation and adsorption. Am J Transplant 2007;7:2195-2199
40. Lai WK, Haydon G, Mutimer D, et al: The effect of molecular adsorbent recirculating system on pathophysiological parameters in patients with acute liver failure. Intensive Care Med 2005;31:1544-1549
41. Lee KH, Lee MK, Sutedja DS, et al: Outcome from molecular adsorbent recycling system (MARS) liver dialysis following drug-induced liver failure. Liver Int 2005;25:973-977
42. Zhou XM, Miao JY, Yang Y, et al: Clinical experience with molecular adsorbent recirculating system (MARS) in patients with drug-induced liver failure. Artif Organs 2004;28:483-486
43. Kantola T, Koivusalo A, Höckerstedt K, et al: The effect of molecular adsorbent recirculating system on survival, native liver recovery, and need for liver transplantation in acute liver failure patients. Transpl Int 2008;21:857-866
44. Camus C, Lavoue S, Gacouin A, et al: Liver transplantation avoided in patients with fulminant hepatic failure who received albumin dialysis with the molecular adsorbent recirculating system while on the waiting list: impact of the duration of therapy. Ther Apher Dial 2009;13:549-555
45. Novelli G, Rossi M, Pretagostini M, et al: One hundred sixteen cases of acute liver failure treated with MARS. Transplant Proc 2005;37:2557-2559
46. Steiner C, Mitzner S: Experiences with MARS liver support therapy in liver failure: analysis of 176 patients of the International MARS Registry. Liver 2002;22(Suppl 2):20-25
47. Camus C, Lavoue S, Gacouin A, et al: Molecular adsorbent recirculating system dialysis in patients with acute liver failure who are assessed for liver transplantation. Intensive Care Med 2006;32:1817-1825
48. Parés A, Deulofeu R, Cisneros L, et al: Albumin dialysis improves hepatic encephalopathy and decreases circulating phenolic aromatic amino acids in patients with alcoholic hepatitis and severe liver failure. Crit Care 2009;13:R8
49. Guo LM, Liu JY, Xu DZ, et al: Application of Molecular Adsorbents Recirculating System to remove NO and cytokines in severe liver failure patients with multiple organ dysfunction syndrome. Liver Int 2003;23(Suppl 3):16-20
50. Koivusalo AM, Kantola T, Arola J, et al: Is it possible to gain extra waiting time to liver transplantation in acute liver failure patients using albumin dialysis? Ther Apher Dial 2009;13:413-418
51. Koivusalo AM, Teikari T, Höckerstedt K, et al: Albumin dialysis has a favorable effect on amino acid profile in hepatic encephalopathy. Metab Brain Dis 2008;23:387-398
52. Kantola T, Koivusalo AM, Parmanen S, et al: Survival predictors in patients treated with a molecular adsorbent recirculating system. World J Gastroenterol 2009;15:3015-3024
53. Kantola T, Mäklin S, Koivusalo AM, et al: Cost-utility of molecular adsorbent recirculating system treatment in acute liver failure. World J Gastroenterol 2010;16:2227-2234
54. Wigg AJ, Gunson BK, Mutimer DJ: Outcomes following liver transplantation for seronegative acute liver failure: experience during a 12-year period with more than 100 patients. Liver Transpl 2005;11:27-34